Status:
COMPLETED
A 56-day Clinical Study on Facial Skin Rejuvenation
Lead Sponsor:
Botanee Group Co., Ltd.
Conditions:
Skin Manifestations
Wrinkle
Eligibility:
FEMALE
30-50 years
Phase:
NA
Brief Summary
This clinical trial aims to learn about the efficacy of MLYAAT-1002® (a proprietary anti-aging complex, MLYAAT is short for "multi-layer anti-ageing technology" ) in female subjects who have newly rec...
Detailed Description
The main expectations are: * After the 8-week continuous use of the test formulations with MLYAAT-1002® on one split-face side, the clinical manifestations and scores of photoaging improve compared t...
Eligibility Criteria
Inclusion
- self-reported facial aging problems such as roughness, fine lines, and dull skin
- no symptoms of itching, tingling, or burning on the face
- no symptoms of facial flushing, erythema, papules, desquamation, or spot haemorrhage as evaluated by a dermatologist
- photodamage scores above 2 (evaluated by a dermatologist)
- compliance with split-face use of the assigned formulations for 56 days
- no antibiotics remedy in the past three months
- regular use of sunscreen products at least five times a week
- no plans to leave Shanghai during the period of the trial
- compliance with no use of any cosmetics that may bias the study results during the period of the trial
- written informed consent and portrait right consent were obtained from all participants before study entry
Exclusion
- female subjects who are pregnant, lactating or planning to become pregnant
- history of alcoholism
- history of allergies
- subjects who have received medical rejuvenation treatment within the past one year
- being a participant in any other clinical trial within the past one month
- subjects who are suffering from facial skin diseases (melasma, acne, and herpes simplex, etc.)
- subjects with scar constitution or that predispose to Koebner's phenomenon (such as vitiligo and lichen planus, etc.)
- subjects who had skin diseases (such as psoriasis, eczema, and skin cancer, etc.)
- taken/injected anti-allergy medication in the past one month
- subjects who had a high fever in the past 2 weeks
- received anticancer chemotherapy or immunotherapy in the past 6 months
- anyone that the investigator thinks of not eligible.
Key Trial Info
Start Date :
November 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06188338
Start Date
November 18 2023
End Date
August 15 2024
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai China-norm Quality Technical Service Co ，Ltd
Shanghai, Shanghai Municipality, China, 200072